FrancophonIA/ELRC3.0 huggingface dataset:
English: Jakavi can relieve the symptoms, reduce spleen size and the volume of red blood cells produced in patients with polycythaemia vera by selectively blocking enzymes called Janus Associated Kinases (JAK1 and JAK2), thus potentially reducing the risk of serious blood or vascular complications.
Croatian: Jakavi može ublažiti simptome, smanjiti veličinu slezene i volumen crvenih krvnih stanica koje se stvaraju u bolesnika s policitemijom verom tako što selektivno blokira enzime koji se zovu Janus kinaze (JAK1 i JAK2) te tako može smanjiti rizik od ozbiljnih komplikacija s krvlju ili krvnim žilama.
English: The median duration of exposure to Jakavi during the randomised study periods was 7.85 months (range 0.03 to 7.85 months).
Croatian: Medijan trajanja izloženosti Jakaviju tijekom razdoblja randomizacije bio je 7,85 mjeseci (raspon 0,03 do 7,85 mjeseci).
English: The following may reduce the effectiveness of Jakavi: - Avasimibe, a medicine to treat heart disease.
Croatian: Sljedeći lijekovi mogli bi smanjiti djelotvornost Jakavija: - Avasimib, lijek za liječenje srčane bolesti.
English: A dose reduction of approximately 50% is recommended for patients with hepatic impairment (see section 4.2).
Croatian: Smanjenje doze od otprilike 50% preporučuje se za bolesnike s oštećenjem jetre (vidjeti dio 4.2).
English: Multipack: 168 (3 packs of 56) tablets.
Croatian: Višestruko pakiranje: 168 (3 pakiranja od 56) tableta.
English: Substances transported by P-glycoprotein or other transporters Ruxolitinib may inhibit P-glycoprotein and breast cancer resistance protein (BCRP) in the intestine.
Croatian: Tvari koje transportira P-glikoprotein ili drugi transporteri Ruksolitinib bi mogao inhibirati P-glikoprotein i protein za rezistenciju na karcinom dojke (engl. breast cancer resistance protein, BCRP) u crijevima.
English: Baseline demographics and disease characteristics were comparable between the two treatments arms.
Croatian: Početne demografske karakteristike i karakteristike bolesti bile su usporedive između dviju terapijskih skupina.
English: Common Terminology Criteria for Adverse Events (CTCAE) version 3.0; grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening d
Croatian: Uobičajeno nazivlje kriterija za štetne događaje (CTCAE) verzija 3.0; stupanj 1 = blaga, stupanj 2 = umjerena, stupanj 3 = teška, stupanj 4 = opasna po život d
English: Jakavi is used to treat adult patients with an enlarged spleen or with symptoms related to myelofibrosis, a rare form of blood cancer.
Croatian: Jakavi se primjenjuje za liječenje odraslih bolesnika s povećanom slezenom ili sa simptomima povezanima s mijelofibrozom, rijetkim oblikom raka krvi.
English: Polycythaemia vera is a disorder of the bone marrow, in which the marrow produce too many red blood cells.
Croatian: Policitemija vera je poremećaj koštane srži u kojem srž stvara previše crvenih krvnih stanica.
English: In both studies, patients had palpable splenomegaly at least 5 cm below the costal margin and risk category of intermediate-2 or high risk based on the International Working Group (IWG) Consensus Criteria.
Croatian: U oba ispitivanja bolesnici su imali splenomegaliju, palpabilnu najmanje 5 cm ispod rebrenog luka i kategoriju rizika umjereni-2 ili visoki rizik na temelju kriterija Međunarodne radne skupine (engl.
English: In clinical studies in MF the total symptom score for MF symptoms gradually returned to baseline value within 7 days after dose discontinuation (see section 4.4).
Croatian: U kliničkim ispitivanjima MF-a ukupni zbroj simptoma za simptome MF-a postupno se vratio na početnu vrijednost u roku od 7 dana od prekida uzimanja doze (vidjeti dio 4.4).
English: Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by scar tissue.
Croatian: Mijelofibroza je poremećaj koštane srži, u kojoj se srž zamjenjuje ožiljnim tkivom.
English: If you have questions about how long to take Jakavi, talk to your doctor or pharmacist.
Croatian: Ako imate pitanja o tome koliko dugo uzimati Jakavi, obratite se svom liječniku ili ljekarniku.
English: A whole body autoradiography study in rats has shown that ruxolitinib does not penetrate the blood-brain barrier.
Croatian: Ispitivanje autoradiografije cijelog tijela u štakora pokazalo je da ruksolitinib ne prodire kroz krvno-moždanu barijeru.
English: PVC/PCTFE/Aluminium blister packs containing 14 or 56 tablets or multipacks containing 168 (3 packs of 56) tablets.
Croatian: PVC/PCTFE/Aluminij blister pakiranja koja sadrže 14 ili 56 tableta ili višestruka pakiranja koja sadrže 168 (3 pakiranja od 56) tableta.
English: BAT was selected by the investigator on a patient-bypatient basis and included hydroxyurea (59.5%), interferon/pegylated interferon (11.7%), anagrelide (7.2%), pipobroman (1.8%) and observation (15.3%).
Croatian: NDT je odabrao ispitivač posebno za svakog bolesnika, a uključivao je hidroksiureju (59,5%), interferon/pegilirani interferon (11,7%), anagrelid (7,2%), pipobroman (1,8%) i promatranje (15,3%).
English: Patients should be closely monitored (e.g. twice weekly) for cytopenias and dose titrated based on safety and efficacy (see section 4.2).
Croatian: Bolesnike treba pažljivo motriti (npr. dvaput tjedno) zbog mogućih citopenija te titrirati dozu na temelju sigurnosti i djelotvornosti (vidjeti dio 4.2).
English: Improvement in perception of treatment benefit was also higher in patients treated with ruxolitinib at week 32 (78% versus 33%).
Croatian: Poboljšanje u percepciji koristi liječenja također je bilo veće u bolesnika liječenih ruksolitinibom u 32. tjednu (78% naspram 33%).
English: Talk to your doctor or pharmacist during your treatment with Jakavi - if you experience unexpected bruising and/or bleeding, unusual tiredness, shortness of breath during exercise or at rest, unusually pale skin, or frequent infections (these are signs of blood disorders).
Croatian: Obratite se svom liječniku ili ljekarniku tijekom liječenja Jakavijem - ako primijetite neočekivane podljeve krvi i/ili krvarenje, neuobičajeni umor, nedostatak zraka tijekom fizičke aktivnosti ili u mirovanju, neuobičajeno blijedu kožu ili učestale infekcije (to su znakovi poremećaja krvi).
English: After recovery of blood counts above these levels, dosing may be re-started at 5 mg twice daily and gradually increased based on careful monitoring of complete blood cell count, including a white blood cell count differential.
Croatian: Nakon povratka krvne slike na vrijednosti iznad tih razina, može se ponovno početi davanje doze od 5 mg dvaput na dan te je postupno povećavati na temelju pažljivog praćenja kompletne krvne slike, što uključuje i diferencijalnu krvnu sliku leukocita.
English: Clearance was 12.7 l/h in PV patients, with a 42% inter-subject variability and no relationship was apparent between oral clearance and gender, patient age or race, based on a population pharmacokinetic evaluation in PV patients.
Croatian: Klirens je bio 12,7 l/h u bolesnika s PV-om, uz varijabilnost između ispitanika od 42% te nije bilo očite povezanosti između oralnog klirensa i spola, bolesnikove dobi ili rase, temeljeno na procjeni populacijske farmakokinetike u bolesnika s PV-om.
English: The mean change in the global health status at week 24, as measured by EORTC QLQ C30 was +12.3 for Jakavi and -3.4 for placebo (p<0.0001).
Croatian: Srednja promjena u općem zdravstvenom statusu u 24. tjednu, mjereno pomoću EORTC QLQ C30, bila je +12,3 za Jakavi i -3,4 za placebo (p<0,0001).
English: In phase 3 clinical studies sepsis was reported in 3.0% of patients.
Croatian: U kliničkim ispitivanjima faze 3 sepsa je bila prijavljena u 3,0% bolesnika.
English: Infections and infestations Urinary tract infections a,d
Croatian: Infekcije i infestacije Infekcije mokraćnog sustava a,d
English: By blocking the action of certain enzymes (called Janus Associated Kinases), Jakavi can reduce the size of the spleen in patients with myelofibrosis and relieve symptoms such as fever, night sweats, bone pain and weight loss in patients with myelofibrosis.
Croatian: Blokiranjem djelovanja određenih enzima (koji se nazivaju Janus kinazama), Jakavi može smanjiti veličinu slezene u bolesnika s mijelofibrozom i ublažiti simptome kao što su vrućica, noćno znojenje, bolovi u kostima i gubitak tjelesne težine u bolesnika s mijelofibrozom.
English: It has not been established whether abrupt discontinuation of Jakavi contributed to these events.
Croatian: Nije ustanovljeno je li nagli prekid liječenja Jakavijem doprinio tim događajima.
English: The following may increase the risk of side effects with Jakavi: - Some medicines used to treat infections.
Croatian: Sljedeći lijekovi mogli bi povećati rizik od nuspojava s Jakavijem: - Neki lijekovi koji se primjenjuju za liječenje infekcija.
English: However, patients should be closely monitored for cytopenias when initiating therapy with a moderate CYP3A4 inhibitor.
Croatian: Međutim, bolesnike treba pažljivo pratiti zbog citopenija kada se započinje liječenje umjerenim CYP3A4 inhibitorom.
English: There is no known antidote for overdoses with Jakavi.
Croatian: Nema poznatog lijeka za predoziranje Jakavijem.
English: - Phenytoin, carbamazepine or phenobarbital and other anti-epileptics used to stop seizures or fits.
Croatian: - Fenitoin, karbamazepin ili fenobarbital i drugi antiepileptici koji se primjenjuju za zaustavljanje konvulzija i napadaja.
English: There was one report of CTCAE grade 3 post-herpetic neuralgia amongst the PV patients.
Croatian: Prijavljen je jedan slučaj postherpetske neuralgije stupnja 3 prema CTCAE-u među bolesnicima s PV-om.
English: No data is available for dosing patients who are undergoing peritoneal dialysis or continuous venovenous haemofiltration (see section 5.2).
Croatian: Nema dostupnih podataka o dozama u bolesnika koji se podvrgavaju peritonejskoj dijalizi ili kontinuiranoj veno-venskoj hemofiltraciji (vidjeti dio 5.2).
English: In the randomised period of the two pivotal studies, COMFORT-I and COMFORT-II, the median duration of exposure to Jakavi was 10.8 months (range 0.3 to 23.5 months).
Croatian: U razdoblju randomizacije dvaju ključnih ispitivanja, COMFORT-I i COMFORT-II, medijan trajanja izloženosti Jakaviju bio je 10,8 mjeseci (raspon 0,3 do 23,5 mjeseci).
English: These were all CTCAE grade 1 and 2 with the exception of one CTCAE grade 3 raised alanine aminotransferase event.
Croatian: Sve su one bile stupnja 1 i 2 prema CTCAE-u, uz iznimku jednog događaja povišene alanin aminotransferaze stupnja 3 prema CTCAE-u.
English: A second randomised, open label, active-controlled phase 3b study (RESPONSE 2) was conducted in 149 PV patients who were resistant to, or intolerant of, hydroxyurea but without palpable splenomegaly.
Croatian: Drugo randomizirano, otvoreno, aktivno kontrolirano ispitivanje faze 3b (RESPONSE 2) bilo je provedeno na 149 bolesnika s PV-om koji su bili otporni na hidroksiureju ili je nisu podnosili, ali bez palpabilne splenomegalije.
English: Frequency category for MF patients
Croatian: Kategorija učestalosti za bolesnike s MF-om
English: Other interactions to be considered affecting ruxolitinib
Croatian: Druge interakcije koje treba uzeti u obzir zbog utjecaja na ruksolitinib
English: Dual CYP2C9 and CYP3A4 inhibitors
Croatian: Dvostruki CYP2C9 i CYP3A4 inhibitori
English: Baseline elevations in inflammatory markers associated with constitutional symptoms such as TNFα, IL-6 and CRP in subjects with MF were decreased following treatment with ruxolitinib.
Croatian: Početna povišenja upalnih markera povezanih s konstitucionalnim simptomima kao što su TNFα, IL-6 i CRP u ispitanika s MF-om bila su smanjena nakon liječenja ruksolitinibom.
English: Juvenile rats are more sensitive than adult rats to ruxolitinib toxicity.
Croatian: Mladi štakori su osjetljiviji na toksičnost ruksolitiniba nego odrasli štakori.
English: Any CTCAE
Croatian: Bilo koji CTCAE
English: In vitro data indicate that ruxolitinib may inhibit P-gp and BCRP.
Croatian: In vitro podaci upućuju na to da bi ruksolitinib mogao inhibirati P-gp i BCRP.
English: A randomised, open-label, active-controlled phase 3 study (RESPONSE) was conducted in 222 patients with PV who were resistant to or intolerant of hydroxyurea defined based on the European LeukemiaNet (ELN) international working group published criteria.
Croatian: Randomizirano, otvoreno, aktivno kontrolirano ispitivanje faze 3 (RESPONSE) bilo je provedeno na 222 bolesnika s PV-om koji su imali otpornost na hidroksiureju ili je nisu podnosili, definirano temeljem objavljenih kriterija međunarodne radne skupne Europske mreže za leukemiju (ELN).
English: Frequency category for PV patients
Croatian: Kategorija učestalosti za bolesnike s PV-om
English: In clinical studies, ruxolitinib is rapidly absorbed after oral administration with maximal plasma concentration (Cmax) achieved approximately 1 hour post-dose.
Croatian: U kliničkim ispitivanjima ruksolitinib se brzo apsorbira nakon peroralne primjene, pri čemu je najviša koncentracija u plazmi (Cmax) bila postignuta otprilike 1 sat nakon uzimanja doze.
English: The starting dose of Jakavi should be reduced by approximately 50% in patients with hepatic impairment.
Croatian: Početnu dozu Jakavija treba smanjiti za otprilike 50% u bolesnika s oštećenjem jetre.
English: Phlebotomy eligibility was defined as a confirmed HCT of >45%, i.e. at least 3 percentage points higher than the HCT obtained at baseline or a confirmed HCT of >48%, depending on which was lower.
Croatian: Prikladnost za flebotomiju bila je definirana kao potvrđeni hematokrit >45%, tj. najmanje 3 postotna boda viši od hematokrita dobivenog na početku ili potvrđeni hematokrit >48%, ovisno o tome koji je bio niži.
English: Similarly, patients with PV also presented with baseline elevations in inflammatory markers and these markers were decreased following treatment with ruxolitinib.
Croatian: Slično tome, bolesnici s PV-om također su imali početna povišenja upalnih markera, a ti su se markeri smanjili uslijed liječenja ruksolitinibom.
English: Avoid the concomitant use of ruxolitinib with fluconazole doses greater than 200 mg daily.
Croatian: Izbjegavajte istodobnu primjenu ruksolitiniba s dozama flukonazola većim od 200 mg dnevno.
English: Upon discontinuation, MF patients may experience a return of MF symptoms such as fatigue, bone pain, fever, pruritus, night sweats, symptomatic splenomegaly and weight loss.
Croatian: Po prekidu liječenja bolesnici s MF-om mogu osjetiti povratak simptoma MF-a kao što su umor, bol u kostima, vrućica, pruritus, noćno znojenje, simptomatska splenomegalija i gubitak tjelesne težine.
English: Jakavi contains lactose (milk sugar).
Croatian: Jakavi sadrži laktozu (mliječni šećer).
English: In the best available therapy arm, 47% of patients received hydroxyurea and 16% of patients received glucocorticoids.
Croatian: U skupini koja je primala najbolju dostupnu terapiju, 47% bolesnika primalo je hidroksiureju, a 16% bolesnika primalo je glukokortikoide.
English: There are no data from the use of Jakavi in pregnant women.
Croatian: Nema podataka o primjeni Jakavija u trudnica.
English: Patients in the ruxolitinib arm had PV diagnosis for a median of 8.2 years and had previously received hydroxyurea for a median of approximately 3 years.
Croatian: Bolesnici u skupini koja je primala ruksolitinib imali su dijagnozu PV-a tijekom medijana od 8,2 godine i prethodno su primali hidroksiureju tijekom medijana od otprilike 3 godine.
English: - ADRs reported are on treatment or up to 28 days post treatment end date.
Croatian: - Prijavljene nuspojave na lijek pojavile su se tijekom liječenja ili do 28 dana nakon zadnjeg dana liječenja.
English: If you interrupt your treatment with Jakavi your myelofibrosis-related symptoms may come back.
Croatian: Ako prekinete liječenje Jakavijem Vaši simptomi povezani s mijelofibrozom mogli bi se vratiti.
English: If you accidentally take more Jakavi than your doctor prescribed, contact your doctor or pharmacist immediately.
Croatian: Ako slučajno uzmete više Jakavija nego što Vam je liječnik propisao, odmah se obratite svom liječniku ili ljekarniku.
English: Haemodialysis is not expected to enhance the elimination of ruxolitinib.
Croatian: Ne očekuje se da će hemodijaliza povećati eliminaciju ruksolitiniba.
English: Based on studies in healthy subjects, no relevant differences in ruxolitinib pharmacokinetics were observed with regard to gender and race.
Croatian: Na temelju ispitivanja u zdravih ispitanika nisu bile uočene relevantne razlike u farmakokinetici ruksolitiniba s obzirom na spol i rasu.
English: Ruxolitinib is mainly metabolised by CYP3A4 (>50%), with additional contribution from CYP2C9.
Croatian: Ruksolitinib se uglavnom metabolizira putem CYP3A4 (>50%), uz dodatni doprinos CYP2C9.
English: It is recommended that, for patients who have demonstrated some degree of clinical improvement, ruxolitinib therapy be discontinued if they sustain an increase in their spleen length of 40% compared with baseline size (roughly equivalent to a 25% increase in spleen volume) and no longer have tangible improvement in disease-related symptoms.
Croatian: Preporučuje se da se u bolesnika kod kojih je vidljiv određeni stupanj kliničkog poboljšanja, terapija ruksolitinibom prekine ako perzistira povećanje u duljini slezene od 40% u usporedbi s početnom duljinom (otprilike ekvivalentno povećanju volumena slezene od 25%) i ako više nemaju opipljivih poboljšanja simptoma povezanih s bolešću.
English: In COMFORT-I and COMFORT-II, patient baseline demographics and disease characteristics were comparable between the treatment arms.
Croatian: U COMFORT-I i COMFORT-II, početne demografske karakteristike bolesnika i karakteristike bolesti bile su usporedive između terapijskih skupina.
English: In a population pharmacokinetic evaluation in MF patients, no relationship was apparent between oral clearance and patient age or race.
Croatian: U ocjenjivanju populacijske farmakokinetike u bolesnika s MF-om nije bilo očite veze između oralnog klirensa i bolesnikove dobi ili rase.
English: Based on a human mass balance study, oral absorption of ruxolitinib, as ruxolitinib or metabolites formed under first-pass, is 95% or greater.
Croatian: Na temelju ispitivanja masene bilance u ljudi, oralna apsorpcija ruksolitiniba, koja obuhvaća ruksolitinib ili metabolite koji se stvaraju uslijed prvog prolaska kroz jetru, je 95% ili veća.
English: MF patients did not become refractory to the pharmacodynamic effects of ruxolitinib treatment over time.
Croatian: Bolesnici s MF-om nisu postali refraktorni na farmakodinamičke učinke liječenja ruksolitinibom tijekom vremena.
English: Jakavi treatment should only be initiated by a physician experienced in the administration of anti-cancer medicinal products.
Croatian: Liječenje Jakavijem smije započeti samo liječnik koji ima iskustva u primjeni antitumorskih lijekova.
English: In the PV population, the CTCAE grade 3 and 4 events were reported in 2.7%, while in the MF patients the frequency was 42.56%.
Croatian: U populaciji s PV-om, događaji stupnja 3 i 4 prema CTCAE-u bili su prijavljeni u 2,7%, dok je u bolesnika s MF-om učestalost bila 42,56%.
English: In animal studies, no effect on fertility was observed.
Croatian: U ispitivanjima na životinjama nije uočen učinak na plodnost.
English: Some are very common (may affect more than 1 in 10 people), some are common (may affect up to 1 in 10 people): - any sign of bleeding in the brain, such as sudden altered level of consciousness, persistent headache, numbness, tingling, weakness or paralysis (common) - any sign of bleeding in the stomach or intestine, such as passing black or bloodstained stools, or vomiting blood (common) - unexpected bruising and/or bleeding, unusual tiredness, shortness of breath during exercise or at rest, unusually pale skin, or frequent infections (possible symptoms of blood disorders) (very common) - painful skin rash with blisters (possible symptoms of shingles (herpes zoster)) (common) - fever, chills or other symptoms of infections (very common) - low level of red blood cells (anaemia), low level of white blood cells (neutropenia) or low level of platelets (thrombocytopenia) (very common)
Croatian: Neke su vrlo česte (mogu se javiti u više od 1 na 10 osoba), neke su česte (mogu se javiti u do 1 na 10 osoba): - bilo koji znak krvarenja u mozgu, kao što je iznenadna promjena razine svijesti, ustrajna glavobolja, obamrlost, trnci, slabost ili paraliza (često) - bilo koji znak krvarenja u želucu ili crijevima, kao što su crna ili krvava stolica ili povraćanje krvi (često) - neočekivane modrice i/ili krvarenje, neuobičajen umor, nedostatak zraka tijekom fizičke aktivnosti ili u mirovanju, neuobičajeno blijeda koža ili česte infekcije (mogući simptomi poremećaja krvi) (vrlo često) - bolni kožni osip s mjehurićima (mogući simptomi herpesa zoster) (često) - vrućica, zimica ili drugi simptomi infekcija (vrlo često) - niska razina eritrocita (anemija), niska razina leukocita (neutropenija) ili niska razina trombocita (trombocitopenija) (vrlo često)
English: Complete blood count, including a white blood cell count differential, should be monitored every 2-4 weeks until Jakavi doses are stabilised, and then as clinically indicated (see section 4.4).
Croatian: Kompletnu krvnu sliku, uključujući i diferencijalnu krvnu sliku leukocita, treba pratiti svaka 2-4 tjedna dok se doze Jakavija ne stabiliziraju, a nakon toga u skladu s kliničkim indikacijama (vidjeti dio 4.4).
English: Post-Authorisation efficacy study to provide long-term efficacy and safety data of ruxolitinib including (late) achievement of response, duration of (various) responses, as well as incidence of AEs including haematological transformation and second malignancies from the study B2301.
Croatian: Ispitivanje djelotvornosti nakon stavljanja lijeka u promet radi pružanja podataka o dugoročnoj djelotvornosti i sigurnosti primjene ruksolitiniba uključujući (kasno) postignute odgovore, trajanje (različitih) odgovora, kao i incidenciju štetnih događaja uključujući hematološku transformaciju i sekundarne malignitete iz ispitivanja B2301.
English: Animal studies have shown that ruxolitinib is embryotoxic and foetotoxic.
Croatian: Ispitivanja na životinjama pokazala su da je ruksolitinib embriotoksičan i fetotoksičan.
English: Anaemia b
Croatian: Anemija b
English: This includes prescription medicines, non-prescription medicines and herbal or alternative medicines.
Croatian: To uključuje lijekove koji se izdaju na recept, lijekove koji se izdaju bez recepta te biljne ili alternativne lijekove.
English: Neutropenia (absolute neutrophil count <500) was generally reversible and was managed by temporarily withholding Jakavi (see sections 4.2 and 4.8).
Croatian: Neutropenija (apsolutni broj neutrofila <500) općenito je bila reverzibilna i kontrolirana privremenim prekidom primjene Jakavija (vidjeti dijelove 4.2 i 4.8).
English: Physicians should educate patients about early signs and symptoms of herpes zoster, advising that treatment should be sought as early as possible.
Croatian: Liječnici trebaju upoznati bolesnike s ranim znakovima i simptomima herpesa zostera, te ih upozoriti da liječenje treba započeti čim je moguće prije.
English: In the clinical study programme the severity of adverse drug reactions was assessed based on the CTCAE, defining grade 1 = mild, grade 2 = moderate, grade 3 = severe and grade 4=life-threatening.
Croatian: U programu kliničkih ispitivanja težina nuspojava na lijek bila je ocijenjena na temelju CTCAE-a, koji definira stupanj 1= blago, stupanj 2= umjereno, stupanj 3= teško i stupanj 4= opasno po život.
English: The predicted oral clearance was 17.7 l/h in women and 22.1 l/h in men, with 39% inter-subject variability in MF patients.
Croatian: Predviđeni oralni klirens bio je 17,7 l/h u žena te 22,1 l/h u muškaraca, uz varijabilnost između ispitanika s MF-om od 39%.
English: Lipid monitoring and treatment of dyslipidaemia according to clinical guidelines is recommended.
Croatian: Preporučuje se praćenje lipida i liječenje dislipidemije prema kliničkim smjernicama.